Report cover image

Chronic Hepatitis B Virus Infection - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 200 Pages
SKU # DEL18679374

Description

Chronic Hepatitis B Virus Infection - Pipeline Insight, 2024



DelveInsight’s, “Chronic Hepatitis B Virus Infection - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Chronic Hepatitis B Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Chronic Hepatitis B Virus Infection Understanding

Chronic Hepatitis B Virus Infection: Overview

Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is often transmitted via body fluids like blood, semen, and vaginal secretions. The majority (more than 95%) of immunocompetent adults infected with HBV can clear the infection spontaneously. Patients can present with acute symptomatic disease or have an asymptomatic infection that is identified during screening for HBV. The clinical manifestations of HBV infection vary in both acute and chronic diseases. During the acute infection, patients can have subclinical or anicteric hepatitis, icteric hepatitis, or less commonly fulminant hepatitis. In chronic infection, patients can have an asymptomatic carrier state, chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatitis B virus is transmitted via percutaneous inoculation or through mucosal exposure with infectious bodily fluids.

""Chronic Hepatitis B Virus Infection - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Hepatitis B Virus Infection pipeline landscape is provided which includes the disease overview and Chronic Hepatitis B Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis B Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence in Chronic Hepatitis B Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve in Chronic Hepatitis B Virus Infection.
This segment of the Chronic Hepatitis B Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Hepatitis B Virus Infection Emerging Drugs
  • Pradefovir: Ligand Pharmaceuticals
Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand’s HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.
  • RG6346: Dicerna Pharmaceuticals
RG6346 is an investigational GalXC™ RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.

Further product details are provided in the report……..

Chronic Hepatitis B Virus Infection: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Hepatitis B Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Chronic Hepatitis B Virus Infection
There are approx. 50+ key companies which are developing the therapies for Chronic Hepatitis B Virus Infection. The companies which have their Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. Phase III include, Ligand Pharmaceuticals.
  • Phases
DelveInsight’s report covers around 55+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
Molecule Type

Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Hepatitis B Virus Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis B Virus Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis B Virus Infection drugs.

Chronic Hepatitis B Virus Infection Report Insights
  • Chronic Hepatitis B Virus Infection Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Chronic Hepatitis B Virus Infection Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Chronic Hepatitis B Virus Infection drugs?
  • How many Chronic Hepatitis B Virus Infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Hepatitis B Virus Infection?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Hepatitis B Virus Infection?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Hepatitis B Virus Infection and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Vedanta Biosciences
  • Gilead Sciences
  • Dong-A ST Co
  • Assembly Biosciences
  • Arbutus Biopharma
  • Vir Biotechnology
  • Antios Therapeutics
  • Ascletis Pharmaceuticals
  • Shanghai HEP Pharmaceutical
  • Romark Laboratories
  • Qilu Pharmaceutical
  • Golden Biotechnology
  • Sunshine Lake Pharma
  • Ascentage Pharma
  • GlaxoSmithKline
  • Janssen Sciences
  • Henlix
  • Enyo Pharma
  • Tasly Tianjin Biopharmaceutical
  • Brii Biosciences
  • Vaxine Pty Ltd
  • Vaccitech limited
  • Zhejiang Palo Alto Pharmaceuticals
  • Suzhou Ribo Life Science
  • PharmaEssentia
  • Nucorion Pharmaceuticals
  • Jiangsu HengRui Medicine
  • Enanta Pharmaceuticals
  • Chong Kun Dang Pharmaceutical
  • Guangzhou Lupeng Pharmaceutical
  • VenatoRx Pharmaceuticals
  • Zhimeng Biopharm
Key Products
  • Pradefovir
  • DA 2802
  • VIR-2218
  • AB-729
  • Selgantolimod
  • ATI-2173
  • ASC42
  • Hepalatide
  • QL-007
  • Antroquinonol
  • HEC121120
  • APG-1387
  • GSK3228836
  • JNJ-73763989
  • JNJ-56136379
  • Vonafexor
  • T101
  • BRII-179
  • aVTP-300
  • PA1010
  • P1101
  • NCO-48
  • HRS5091
  • EDP-514
  • CKD-388
  • LP-128
  • VNRX 9945
  • ZM-H1505R
  • ISA104
  • RG6346
  • HepTcell
  • RO7049389
  • RO7020531

Table of Contents

200 Pages
Introduction
Executive Summary
Chronic Hepatitis B Virus Infection : Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Hepatitis B Virus Infection – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Pradefovir: Ligand Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
RG6346: Dicerna Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
VIR-3434: Vir Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
SBT8230: Silverback Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Hepatitis B Virus Infection Key Companies
Chronic Hepatitis B Virus Infection Key Products
Chronic Hepatitis B Virus Infection - Unmet Needs
Chronic Hepatitis B Virus Infection - Market Drivers and Barriers
Chronic Hepatitis B Virus Infection - Future Perspectives and Conclusion
Chronic Hepatitis B Virus Infection Analyst Views
Chronic Hepatitis B Virus Infection Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us